Medicine
Mimrylo kit
Mimrylo kit is a prescription medicine containing Rusfertide for subcutaneous use, marketed by Takeda Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Storage as on the product label
Key facts
- Active ingredient (INN)
- Rusfertide
- Brand
- Mimrylo
- Dosage form
- Kit
- Route
- Subcutaneous
- Packs
- 1 kit and 2 more
- Marketing authorisation holder
- Takeda Pharmaceuticals
- Manufacturer
- Takeda Pharmaceuticals
- Origin register
- US FDA, United States
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 August 2026
- Identifiers
- NDC 63020-735, 63020-765, 63020-745 +2Application NDA220605
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 9.5 injection, powder, lyophilized, for solution in 1 vial, single-dose * .6 mL in 1 syringe | 63020-715-10 | Takeda Pharmaceuticals | 28 August 2026 |
| 1 kit in 1 carton * 19 injection, powder, lyophilized, for solution in 1 vial * .6 mL in 1 syringe | 63020-725-20 | Takeda Pharmaceuticals | 28 August 2026 |
| 1 kit in 1 carton * 28 injection, powder, lyophilized, for solution in 1 vial * .6 mL in 1 syringe | 63020-735-30 | Takeda Pharmaceuticals | 28 August 2026 |
| 1 kit in 1 carton * 41 injection, powder, lyophilized, for solution in 1 vial * .6 mL in 1 syringe | 63020-745-40 | Takeda Pharmaceuticals | 28 August 2026 |
| 1 kit in 1 carton * 54 injection, powder, lyophilized, for solution in 1 vial * .6 mL in 1 syringe | 63020-765-60 | Takeda Pharmaceuticals | 28 August 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 August 2026 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Clinical information for Rusfertide is on its overview page.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RusfertideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- US FDA NDC directory · Checked 12 November 2026
Need Mimrylo kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.